TriSalus Life Sciences, Inc. (TLSI)

TriSalus completed its merger with MedTech Acquisition Corporation in August 2023, leading to its common stock and warrants commencing trading on the Nasdaq Global Market. The company reported its Second Quarter 2025 financial results, announcing $11.2 million in revenue, a 52% increase year-over-year, and reiterated its 2025 revenue guidance of at least 50% growth. In November 2025, TriSalus Life Sciences reported its Third Quarter 2025 results, with an EPS of -$0.96, missing the consensus estimate, and revenue of $11.57 million, slightly below estimates. The company launched the TriNav® XP Infusion System in November 2025, expanding its Pressure-Enabled Drug Delivery™ portfolio. TriSalus announced a virtual KOL event in December 2025 to discuss the TriNav Infusion System for the treatment of symptomatic thyroid disease. In January 2026, TriSalus Life Sciences announced preliminary unaudited Fourth Quarter and Full-Year 2025 results, anticipating approximately $13.2 million in Q4 2025 revenues and $45.2 million for the full year, exceeding its 2025 guidance of 50% annual revenue growth, and provided 2026 revenue guidance of approximately $60 million to $62 million. The stock has experienced daily fluctuations, with prices ranging from approximately $4.60 to $5.22 in early February 2026, and has seen a -14.720% change over the past year, with a 52-week range between $3.42 and $7.95.

The available information does not explicitly indicate demand seasonality for TriSalus Life Sciences' products and services. The company has consistently reported strong revenue growth driven by increased selling resources and market share, and has provided optimistic revenue guidance for upcoming periods, suggesting a steady or growing demand rather than seasonal fluctuations.

TriSalus Life Sciences, Inc. is an oncology-focused medical technology company dedicated to improving the delivery of therapeutics for liver and pancreatic tumors, operating within the Healthcare sector, specifically in the Medical Devices and Drug Delivery industry. The company focuses on developing and commercializing innovative solutions for patients with solid tumors, particularly those in the liver and pancreas, revolving around its proprietary Pressure-Enabled Drug Delivery (PEDD) approach. The TriNav Infusion System is an FDA-cleared device utilizing PEDD for hepatic arterial infusion of liver tumors, including the TriNav FLX and TriNav XP Infusion Systems. The Pancreatic Retrograde Venous Infusion System is an FDA-cleared device employing PEDD for pancreatic tumors. Nelitolimod (SD-101) is an investigational clinical-stage immunotherapy, specifically a class C Toll-like receptor 9 (TLR9) agonist, being explored for its integration with PEDD technology for various liver and pancreatic indications.

TriSalus Life Sciences, Inc. is headquartered in Westminster, Colorado, United States. While financial data indicates operations within the United States, specific details regarding a broader international geographic footprint for product sales or operations are not extensively detailed.

TriSalus Life Sciences has maintained a positive brand reputation, characterized by strong commercial momentum and growing clinical adoption of its TriNav product suite and PEDD platform. The company has also engaged in strategic research collaborations, such as with The University of Texas MD Anderson Cancer Center, to evaluate its investigational immunotherapy SD-101 in combination with checkpoint inhibition. The launch of new products like TriNav FLX and TriNav XP further indicates a commitment to innovation and market expansion. No significant events negatively impacting the company's reputation were found.

TriSalus Life Sciences, Inc. has 109 institutional owners and shareholders, collectively holding 10,470,665 shares. Major institutional owners include Nantahala Capital Management, LLC, Vanguard Group Inc, AWM Investment Company, Inc., Gilder Gagnon Howe & Co Llc, and BlackRock, Inc. Insider ownership stands at 40.92%.